ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,942.47
1.26%
Dow Jones
42,732.13
0.80%
US Dollar vs MXN
20.6314
0.00%
Brent Oil
76.495
0.00%
Bitcoin
98,298.44
0.09%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Reino Unido
  5. LSE

  6. Oxurion Nv (0G99) Cotización

Oxurion Nv

Oxurion Nv (0G99)

LSE
48,800.00
0.00
(0.00%)
Cerrado 05 Enero 10:30AM
Delayed by 15 minutes

Herramientas de nivel profesional para inversores individuales.

Premium

Estadísticas y detalles clave

Último Precio
48,800.00
Postura de Compra
0.00
Postura de Venta
0.00
Volume Operado de la Acción
0.00
0.00 Rango del Día 0.00
48,800.00 Rango de 52 semanas 48,800.00
Capitalización de Mercado [m]
170.286T
Precio Anterior
48,800.00
Precio de Apertura
-
Hora
(O)
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
0.00
Acciones en circulación
3,489,459,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-44.44
Beneficio por acción (BPA)
-0.01
turnover
154k
Beneficio neto
-18.97M

Acerca de Oxurion Nv

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.oxurion.com
Sede
Leuven, Flemish Brabant, Bel
Fundado
-
Oxurion Nv is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0G99. The last closing price for Oxurion Nv was 48,800.00 €. Over the last year, Oxurion Nv shares have traded in a share price range of 48,800.00 € to 48,800.00 €.

Oxurion Nv currently has 3,489,459,000 shares in issue. The market capitalisation of Oxurion Nv is 170.29 € trillion. Oxurion Nv has a price to earnings ratio (PE ratio) of -44.44.

0G99 Últimas noticias

Más noticias

Oxurion Share Consolidation

Oxurion Share Consolidation Oxurion Share Consolidation Leuven, BELGIUM – July 25, 2024 – 06:00 PM CET Oxurion NV (Euronext Brussels: OXUR) (the Company), a biopharmaceutical company based in...

25 Julio 2024
UK Regulatory

Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024

Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024 Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024 Leuven, BELGIUM – 24 July...

24 Julio 2024
UK Regulatory

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Information on the Total Number of Voting Rights (Denominator) following Conversion Notice...

19 Julio 2024
UK Regulatory

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – July 18, 2024 –...

18 Julio 2024
UK Regulatory

Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024

Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024 Oxurion provides clarification on the agenda of the extraordinary...

11 Julio 2024
UK Regulatory

Oxurion signs a Letter of Intent and enters into exclusive negotiations to potentially acquire a pioneering French CRO in stem cell production

Oxurion signs a Letter of Intent and enters into exclusive negotiations to potentially acquire a pioneering French CRO in stem cell production Oxurion signs a Letter of Intent and enters into...

08 Julio 2024
UK Regulatory

Oxurion announces the results of the Extraordinary General Meeting (EGM) held on 4 July 2024 and convenes a new EGM on 24 July 2024

Oxurion announces the results of the Extraordinary General Meeting (EGM) held on 4 July 2024 and convenes a new EGM on 24 July 2024 Oxurion announces the results of the Extraordinary General...

04 Julio 2024
GlobeNewswire Inc.

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – June 7, 2024...

07 Junio 2024
GlobeNewswire Inc.

Oxurion Announces Extraordinary General Shareholders’ Meeting

Oxurion Announces Extraordinary General Shareholders’ Meeting Oxurion Announces Extraordinary General Shareholders’ Meeting Leuven, BELGIUM – June 4, 2024 – 07:00 PM CET – Oxurion NV...

04 Junio 2024
GlobeNewswire Inc.

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – May 27, 2024...

27 Mayo 2024
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10048800488004880000DE
400488004880048800048800DE
1200488004880048800048800DE
2600488004880048800596048800DE
5200488004880048800522848800DE
1560048800488004880013844448800DE
260004880048800488008325848800DE

0G99 - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Oxurion Nv?
El precio actual de las acciones de Oxurion Nv es 48,800.00 €
¿Cuántas acciones de Oxurion Nv están en circulación?
Oxurion Nv tiene 3,489,459,000 acciones en circulación
¿Cuál es la capitalización de mercado de Oxurion Nv?
La capitalización de mercado de Oxurion Nv es EUR 170.29T
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Oxurion Nv?
Oxurion Nv ha negociado en un rango de 48,800.00 € a 48,800.00 € durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Oxurion Nv?
El ratio precio/beneficio de Oxurion Nv es -44.44
¿Cuál es la moneda de reporte de Oxurion Nv?
Oxurion Nv presenta sus resultados financieros en EUR
¿Cuál es el último ingresos anual de Oxurion Nv?
El último ingresos anual de Oxurion Nv es EUR 154k
¿Cuál es el último beneficio anual de Oxurion Nv?
El último beneficio anual de Oxurion Nv es EUR -18.97M
¿Cuál es la dirección registrada de Oxurion Nv?
La dirección registrada de Oxurion Nv es GASTON GEENSLAAN 1, LEUVEN, FLEMISH BRABANT, B-3001
¿Cuál es la dirección del sitio web de Oxurion Nv?
La dirección del sitio web de Oxurion Nv es www.oxurion.com
¿En qué sector industrial opera Oxurion Nv?
Oxurion Nv opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
TCFTheracryf Plc
0.725p
(38.10%)
7.56M
NMTNeometals Ltd
3.50p
(27.27%)
346.81k
SCHOScholium Group Plc
44.00p
(25.71%)
30.65k
FABFusion Antibodies Plc
10.15p
(24.54%)
3.34M
PYXPyx Resources Limited
3.49p
(22.24%)
8.43k
TM1Technology Minerals Plc
0.125p
(-24.24%)
37.21M
QUIZQuiz Plc
0.70p
(-18.60%)
3.67M
SYMESupply@me Capital Plc
0.003p
(-17.81%)
168.35M
OBDOxford Biodynamics Plc
1.20p
(-14.29%)
827.83k
ZENZenith Energy Ltd.
5.25p
(-13.93%)
5.39M
TRPTower Resources Plc
0.0395p
(5.33%)
539.51M
CPXCap-xx Limited
0.1825p
(1.39%)
494M
NTVONativo Resources Plc
0.0019p
(0.00%)
320.16M
DGIDg Innovate Plc
0.0225p
(-13.46%)
208.21M
ENETEthernity Networks Ltd
0.1125p
(2.27%)
207.56M

Discusión

Ver feed completo
sand sand 6 minutos hace
Thank you Ducci for all your sharing and insights extremely helpful. I'm slowly diligently getting there rewiring the brain and focusing on what shows the moves. Much continued success this week. Thank you again.
SPY
mining101 mining101 6 minutos hace
Moving hard soon 
EFSH
mining101 mining101 8 minutos hace
Superb
MEGL
benz280c benz280c 15 minutos hace
Speak louder and maybe you will convince somebody that this is how you really feel. No need to be insecure around your fellow investors.
GDVM
rx7171 rx7171 21 minutos hace
In addition MABs are approved for only a limited portion of the AD population, whereas Blarcamasine appears to be effective in 70-80% of the ITT population with its strongest efficacy in the 70% with wild type Sigma-1.
AVXL
TheHound TheHound 22 minutos hace
Learn how to use the bull market support band with that chart and you’ll have a powerful tool under your belt!
XRPUSD
Investor2014 Investor2014 25 minutos hace
When I say that the totality of information is what Anavex rely on it does take into account the pretty ineffective SOC, associated risks and inconveniences for patients.

Still any drug regulatory process must and should look carefully at the data to ensure that neither type one or tw
AVXL
nowwhat2 nowwhat2 31 minutos hace
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
BTCUSD
rx7171 rx7171 32 minutos hace
Yes that spike to $23 in June of 2021 was driven entirely by the excellent Phase II data for PDD.

Yet now after completing the AD 2b/3 trial and having an EMA MAA accepted for evaluation the share price is barely half that number!

I understand the company being very ca
PDD
sunspotter sunspotter 36 minutos hace
Black Cat Moan was one of my favorites back in the day:

https://youtu.be/cxN-frB1UbI?si=Ph6XMC3omR0rRlmR

Edit: auto correct changed Moan to Moana. The cultural prevalence of Disney.
Investor2014 Investor2014 39 minutos hace
The ex-biotech executive is back in the Rett trap posting mode - hope it goes better with the biased approach this time.

Listing all the site PI’s is not world class peer review WGT confirmation.
AVXL
nowwhat2 nowwhat2 39 minutos hace
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
sunspotter sunspotter 42 minutos hace
I rather think you missed the point. It’s not that higher doses of GALT’s drug are toxic, it’s that they are ineffective.

Given the purported mechanism, that almost certainly means lower doses are too, and that the implication that the lower dose worked is merely an artefact.
GALT
nowwhat2 nowwhat2 44 minutos hace
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
XRPUSD
CrossFireTrader CrossFireTrader 47 minutos hace
I try to avoid Krispy Kreme's af all costs. Thanks for your insight...
GDVM
skitahoe skitahoe 48 minutos hace
Dstock, you may be very right about the data from compassionate use being included, but if it is, I would think that the protocols used on every one of those patients would need to be included as none are specifically on the trial protocol. It's essentially anecdotal evidence, but it could all add
NWBO
Pickme2 Pickme2 49 minutos hace
Stop wasting our time with your ongoing Manipulated nonsense.... Just read the S-1 
Filed with the sec.... 


ATMH
georgejjl georgejjl 50 minutos hace
The MABs are no where near being the standard of care for treating Alzheimer’s patients.
AVXL
benz280c benz280c 52 minutos hace
Phone died when responding to that. In summary, I think the 24/7 is multi-pronged. It is necessary for the kind of business that Veemost is and will be, which aligns it and will help it qualify for Gold. I do not recall it expressly said that Gold was reached and turned down. Not saying that didn't
GDVM
Sheepdog Sheepdog 1 hora hace
Really? So you think the SEC is going to start arresting OTC Scammers and Pump/Dumpers? I hope so...about time.
GCAN
Hummingbird2 Hummingbird2 1 hora hace
$GTII ~ Just listen in the first 5 mins about $GTII 🛫 after March? https://www.youtube.com/watch?v=Ag2f2rDlq5g
GTII
Jane1999 Jane1999 1 hora hace
Here the CEO : https://www.wsj.com/market-data/quotes/CA/XCNQ/TWOH/company-people/executive-profile/149699
TWOH
Curious Bystander Curious Bystander 1 hora hace
The Expert Market was set up by the SEC for several very specific reasons. But you could generally say that a security lands in that market when a company is either UNABLE or UNWILLING to file certain SEC-required forms.

UNABLE or UNWILLING. Hmmmm…..I wonder which category Quantum
FLCX

Su Consulta Reciente

LSE
0G99
Oxurion Nv
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados